Yes I did notice that. Well the second clause is anyone's guess. Noone can reliably predict whether aducanumab will get approved or not. US$7.5m EBIT seems achievable though. I'm waiting to see the sales of contracts for the September quarter. July and August we had $6.5m sales and I'm hoping to see the number in the $10m range. We had $7.7m in September quarter 2019 and if we have close to $10m, I'd be assured that we are tracking very well coming out of pandemic.I wonder if cgs will benefit from the tax relief program to businesses released last night by frydenberg? Some tax exemption for cgs will definitely see CGS profitable this financial year.
Ann: Expansion of executive team - key scientific appointments, page-4
Add to My Watchlist
What is My Watchlist?
